Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions.
Consistency in composition and potency, particularly regarding major allergens, is crucial for the quality of extracts for allergen immunotherapy.



To characterize the major allergen composition of house dust mite (HDM) extracts commercially available in the United States and the SQ HDM sublingual immunotherapy (SLIT) tablet, and to relate the composition to patient sensitization patterns.



Der 1/Der 2 ratios were determined in 10,000- and 30,000-AU/mL HDM extracts from 5 US companies and the SQ HDM SLIT-tablet. Allergen content was analyzed by enzyme-linked immunosorbent assay and compared with an in-house reference. Sensitivity toward Der p 1, Der p 2, and Der p 10 was determined in serum from randomly selected subgroups of 220 individuals from North American and European SQ HDM SLIT-tablet trials.



Mean Der 1/Der 2 ratios in US HDM extracts ranged from 0.4 to 20.5. For the SQ HDM SLIT-tablet (20 batches), variability did not exceed 12% regarding content of Der f 1 (SD, 11.9%; 95% confidence interval [CI], 0.94-1.06), Der p 1 (SD, 6.1%; 95% CI, 0.97-1.03), and combined Der 2 allergen (SD, 6.4%; 95% CI, 0.97-1.03), indicating a consistent Der 1/Der 2 ratio. High allergen sensitivity frequencies toward Der p 1 and Der p 2 were observed regardless of geographic region. Efficacy of the SQ HDM SLIT-tablet has been demonstrated in 5 clinical trials.



The SQ HDM SLIT-tablet has efficacy potential for a broad range of patients because it includes a consistent 1:1 ratio of the 2 major HDM allergens to which individuals were most frequently sensitized across geographic regions. Efficacy has been demonstrated.
Merck & Co Inc, Kenilworth, New Jersey. Electronic address: hendrik.nolte@merck.com.
Hendrik
H
Nolte
ALK, Round Rock, Texas.
Greg
G
Plunkett
ALK, Hørsholm, Denmark.
Karin
K
Grosch
ALK, Hørsholm, Denmark.
Jorgen Nedergaard
JN
Larsen
ALK, Hørsholm, Denmark.
Kaare
K
Lund
Merck & Co Inc, Kenilworth, New Jersey.
Mirko
M
Bollen
D000485:Allergens / Q000032:analysis* / Q000276:immunology; D039741:Antigens, Dermatophagoides / Q000032:analysis* / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000097:blood / Q000517:prevention & control; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D009864:Ontario; D011792:Quebec; D016032:Randomized Controlled Trials as Topic; D063729:Sublingual Immunotherapy / Q000592:standards*; D013607:Tablets / Q000737:chemistry*; D014481:United States
D000485:Allergens; D039741:Antigens, Dermatophagoides; D013607:Tablets; D007073:Immunoglobulin E